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KEY POINTS
Question. To evaluate the relationship between maternal prescription opioid use and incidence of
neurodevelopmental disorders in children.
Findings. In this retrospective cohort study, 7.6% of eligible children were exposed to prescription
opioids during pregnancy. We observed no overall association between maternal prescription opioid use
and the risk of neurodevelopmental disorders in children. However, significantly increased risks were
observed in children with longer-term opioid exposure or high cumulative doses.
Meaning. These findings suggest the need for a careful consideration of the benefits of opioid therapy
during pregnancy versus potential risks of long-term neurodevelopmental disorders in children.
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ABSTRACT
Importance. Little is known regarding long-term effects of fetal opioid exposure on the
neurodevelopment of children.
Objective. To quantify the association between prenatal opioid exposure from maternal prescription use
and long-term neurodevelopmental outcomes in children.
Design. Retrospective cohort study using administrative claims submitted to a large commercial
insurance database.
Setting and Participants. We included pregnant women aged 12 – 55 years and their live-birth infants
born from 2010 to 2012 present in Optum’s deidentified Clinformatics® Data Mart Database. Infants
born to eligible mothers were followed till occurrence of primary outcome, loss to follow-up, or study
end (December 31, 2017), whichever came first.
Exposures. Infants were considered exposed if their mothers filled ≥1 opioid prescription during
pregnancy.
Main outcomes and measures. The primary outcome was neurodevelopmental disorders; a composite
of developmental disorders, intellectual disabilities, and other relevant mental disorders in children.
Propensity score by fine-stratification was applied to adjust for confounding. Hazard ratios (HR) and 95%
confidence intervals (CI) were estimated with Cox proportional hazard models. Sensitivity analyses were
conducted to examine the effects of maternal opioid use by cumulative exposure dichotomized as shortterm (<14 days), by long-term use (≥14 days), cumulative dose (low dose: < 37.5 MME or high dose:
≥37.5 MME), and by trimesters.
Results. We included 24,731 mothers and their 24,912 live-born children of whom 7.6% (1,899) were
exposed to prescription opioids during pregnancy. Overall, 2,138 children were diagnosed with
neurodevelopmental disorders, with incidence rates of 42.0 per 1000 person-years in exposed children
vs. 34.7 per 1000 person-years in unexposed children. Following adjustment for confounding, there was
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no overall association between fetal opioid exposure and risks of neurodevelopmental disorders (HR:
1.16 [0.99, 1.34]). However, significantly increased risks were observed in children with longer
cumulative duration of fetal opioid exposure (adjusted HR: 1.59 [1.03, 2.45]) or high cumulative doses
(adjusted HR: 1.25 [1.01, 1.55]).
Conclusion and Relevance. We observed an increased risk of children neurodevelopmental disorders in
women taking opioid for longer duration and at higher doses during pregnancy. Additional studies are
needed to confirm these findings.
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INTRODUCTION
Pain syndromes are common during pregnancy.1,2 Maternal opioid use has steadily increased in the past
decade, with one in every five pregnant woman estimated to receive opioids during pregnancy.3,4
Maternal use of opioids has been associated with several negative maternal and fetal outcomes
including altered fetal growth and congenital malformations.5–10 Birth defects have been associated with
cognitive impairments and lower academic performance in childhood.11,12 Similar findings have also
been reported in animal studies where exposure of rodents to opioids during critical developmental
periods induced neuronal apoptosis,13–15 and was associated with structural and functional alterations.16
Little is known about the effects of maternal prescription opioid use on the neurodevelopmental
outcomes of children. So far, knowledge of the potential long-term effects of fetal opioid exposure have
been primarily aggregated from studies investigating cognitive impairment in relationship with birth
defects11,12 or small sample sizes conducted in women with opioid use disorders (OUD) or illicit drug use
during pregnancy (eTable 1 in the Supplement).17–21 These findings are however not generalizable to
offspring of mothers receiving prescribed opioids because women with OUD or a history of illicit drug
use are more likely to have higher incidence of comorbid conditions; higher likelihood of smoking,
cocaine, alcohol or other drug use; or socioeconomic factors that can markedly increase the risk of
neurodevelopmental disorders in the developing fetus.19,21,22 Moreover, it is unknown whether the
potential effects of opioids on neurodevelopment differs by trimester, cumulative dose, or duration of
use. Therefore, we conducted a population-based study to quantify the association of gestational
prescription opioid exposure on long-term neurodevelopmental outcomes in children.
METHODS
Data Source
This study was conducted using administrative claims from January 1, 2010 to December 31, 2017 to
Optum’s deidentified Clinformatics® Data Mart Database; a large Commercial and Medicare Advantage
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claims database.23 This study was approved by the institutional review board of University of Rhode
Island. Information on the algorithm for identifying deliveries, mother-infant linkage, estimation of date
of birth and validation results using linked Rhode Island Medicaid data, opioid utilization after
pregnancy, and timing of prenatal test screening is available in the supplementary method.
Pregnancy Window
The pregnancy window was defined by the estimated delivery date and last menstrual period (LMP). The
LMP was calculated by subtracting 35 weeks for preterm births (identified using ICD-9 diagnosis codes:
644.0, 644.2, and 765.x), and 39 weeks for full-term births from estimated delivery date.24
Inclusion/Exclusion Criteria
The study cohort comprised of mothers aged 12 to 55 years and their liveborn infants born between
study start and December 31, 2012. Mothers were required to have continuous insurance eligibility 3
months prior to the estimated LMP to one month following live birth. We excluded mothers with
diagnosis of cancer or OUD during baseline or pregnancy;25,26 women exposed to confirmed teratogenic
medication during pregnancy; and women or infants with ≥1 inpatient or ≥2 outpatient claims indicating
chromosomal abnormality during pregnancy or one month after live-birth. The study cohort selection
diagram and operational definitions for the various exclusion criteria are presented in Figure 1 and
eTable2 respectively.
Opioid Exposure
Prescription opioids in our analysis included single or combination products of hydrocodone, oxycodone,
codeine, fentanyl, hydromorphone, meperidine, methadone, oxymorphone, dihydrocodeine,
tapentadol, levorphanol, tramadol, transdermal buprenorphine, pentazocine, or morphine. To allow
meaningful comparisons between different opioid medications, opioid doses were converted to
morphine milligram equivalents (MMEs) using opioid-conversion tables.27
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Infants were considered exposed if their mother filled ≥1 opioid prescription during pregnancy and
unexposed if their mothers did not fill a prescription of eligible opioids anytime during the baseline and
pregnancy period. We additionally required no filling of opioid prescriptions during the baseline period
in the reference group to prevent exposure misclassification arising from women who may still have
opioids remaining from an earlier prescription, but available at the start of pregnancy. As such, mothers
who filled opioids during baseline, but not during pregnancy were excluded.
Outcome Assessment
The primary endpoint was a composite of relevant mental disorders (henceforth regarded as
neurodevelopmental disorders) in the infant, based on categories listed in Halloran et al.28 To facilitate
comparison with previous research, developmental disorders - a subcategory of the primary outcome was analyzed as a secondary outcome. The primary and secondary outcomes were assessed on the basis
of the presence of ≥1 inpatient or outpatient ICD-9 or ICD-10 diagnosis in children claims (eTable 3 in the
Supplement). Following delivery, live-birth infants born to eligible mothers before December 31, 2012
(inclusive) were then followed until first diagnosis of neurodevelopmental disorders, lost to follow-up, or
December 31, 2017 (the study end date), whichever came first.
Covariates
We considered known and suspected risk factors, and their proxies for adjustment in our analyses. The
covariates taken into consideration were grouped as maternal sociodemographic characteristics,
maternal comorbidities and mental health diagnoses, concomitant drug use, and measures of burden of
illnesses such as the Obstetric Morbidity Index.29 A complete list of the covariates and the time of
assessment is available in eTable4.
Statistical Analysis
Cox proportional-hazard models were used to estimate the absolute rates (per 1000 person years) and
hazards ratio (HR) with their 95% confidence intervals. Analyses of Schoenfeld residuals showed no
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violations of the proportional hazards assumption.30 In the adjusted analyses, we accounted for
potential confounding by creating 50 equally sized propensity score (PS) strata based on the PS
distribution among the opioid exposed women, and then weighted the untreated group in the final
outcome model using the distribution of the exposed group.31 Following covariate adjustment, the
maximum allowed standardized difference between the treatment groups was 0.1. Considering that we
included mothers with multiple pregnancies, we accounted for correlation between siblings by using the
Huber sandwich estimator for correction of standard errors.32 All analyses were conducted using SAS 9.4
(SAS Institute Inc).
Secondary analysis
Teratogens are often dose-dependent; therefore, we evaluated for the presence of a dose-response
relationship between fetal opioid exposure and the risk of neurodevelopmental disorders using two
approaches. First, exposed infants were dichotomized by median cumulative opioid dose (in MME) into
low and high cumulative dose (<37.5 and ≥37.5 MME respectively) and compared with unexposed
infants. Second, we assessed the relationship between duration of exposure – dichotomized by
cumulated days’ supply into “short-term” (<14 days) and “long-term exposure” (≥ 14 days) - and the
incidence of neurodevelopmental disorders. We regarded ≥14 cumulative days of opioid use as “longterm opioid exposure” based on previous research indicating that long-term opioid use is infrequent in
pregnancy and the median of the total days of opioid supply during pregnancy is often less than two
weeks.33
Sensitivity analyses
To our knowledge, little-to-nothing is known regarding the etiologically relevant gestational window
between prenatal opioid exposure and neurodevelopmental disorders. Therefore, we conducted
secondary analyses to assess the relationship between opioid exposure during specific trimesters - first
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trimester (LMP to 90 days of pregnancy), second trimester (91 to 180 days of pregnancy), third trimester
(181 days of pregnancy till date of birth) and the incidence of neurodevelopmental disorders.
To address the issue of exposure misclassification during specific trimester or during pregnancy, we
repeated our primary analyses using an alternative exposure definition based on overlapping days of
supply. Exposure misclassification can potentially occur with our primary exposure definition if, for
example, a mother filled an opioid prescription close to the end of a trimester but had days of supply
from previous prescription extending into the subsequent trimester. As such, infants were considered
exposed during pregnancy or a specific trimester if the days’ supply of opioid(s) overlapped with the
pregnancy window or any trimester. Next, to overcome concerns of potential outcome misclassification,
we redefined our primary outcome using two separate approaches: (a) requiring ≥2 hospital contacts for
neurodevelopmental disorders; and (b) the presence of ≥2 neurodevelopmental disorders related claims
on two separate days. Finally, to mitigate confounding by underlying indications for opioids, we
performed two additional analyses. First, we repeated our primary analysis in a restricted cohort of
children born to mothers with diagnosis of pain conditions, mental disorders or receipt of psychotropic
medications. Second, we further adjusted the restricted cohort for confounding by other prespecified
covariates.
RESULTS
Patients
Overall, 24,731 mothers with their 24,912 live-born infants were included in our analyses (Figure 1).
There were 7.6% (n=1,899) infants exposed to prescription opioids during pregnancy. In four of every
five exposed infants (81%, n=1,538), their mothers filled only one prescription of opioids during
pregnancy; cumulative median dose and days of supply were 37.5 MME (2.9, 2205 MME) and 5.0 days
(1, 392) respectively. Additional results on opioid utilization is presented in eTable5 in the Supplement.
The median (interquartile range) and average (standard deviation (SD)) follow-up time for included
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infants were 681 (252, 1397) and 890 (748.3) days respectively; the minimum and maximum follow-up
time were 0 and 2558 days respectively. Prior to propensity score adjustment, compared to mothers
who were unexposed, mothers who received opioids during pregnancy were older; generally had higher
prevalence of tobacco use, maternal illnesses and comorbidities; and concomitant medications use
(Table 1).
Outcomes
We identified 2,138 infants with neurodevelopmental disorders with 187 (9.9%) in prenatally opioidexposed vs. 1,951 (8.5%) in unexposed infants. The crude incidence rate among exposed and unexposed
infants was 42.0 and 34.7 per 1000 person-years (PY) respectively, equivalent to an unadjusted HR and
95% CI of 1.22 [1.05, 1.41]) (Table 2). Following propensity-score adjustment, the risk of
neurodevelopmental disorders in infants exposed prenatally to opioids was further attenuated and not
statistically significant (HR: 1.16 [0.99, 1.34]). A similar finding of no significant association following
adjustment was observed with our secondary outcome; developmental disorders (HR: 1.10 [0.89, 1.36])
(Table2).
Secondary analyses
Children exposed to high cumulative opioid doses during pregnancy vs. unexposed children had
increased risk of neurodevelopmental disorders (adjusted HR: 1.21 [1.01, 1.49]). Similarly, children
whose mothers received at least 14 cumulative days’ supply of opioids had significantly increased risks
of neurodevelopmental disorders compared with unexposed children (adjusted HR: 1.66 [1.10, 2.48])
(Table 3).
Sensitivity analyses
We observed no significant association between maternal use of opioids during any specific trimester,
and with alternative outcome or exposure definitions (Table 3, eTable 6). Due to sample size restrictions,
we were unable to assess the relationship between maternal opioid use during ≥2 trimesters and
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neurodevelopmental disorders in children. When we restricted our analyses to children whose mothers
had pain or mental disorders conditions, or received psychotropic medications, we found no significant
association after covariate adjustment (HR: 1.16 [0.94, 1.33]).
DISCUSSION
Although our findings showed an absent of significantly increased risks of neurodevelopmental disorders
in children born to mothers who received prescription opioids anytime in pregnancy, or during specific
trimesters of pregnancy, we observed significantly increased risks of neurodevelopmental disorders in
children whose mothers received ≥14 days’ cumulative opioid supply or higher opioid doses during
pregnancy. These findings highlight the potential dangers of longer duration and higher doses of
prenatal opioid exposure on children’s neurodevelopment and are consistent with the known
dose/exposure effects of teratogens on risks for malformations and neurodevelopmental outcomes. The
majority of prescription opioid use in pregnancy is reportedly to manage acute pain,6 often prescribed at
lower doses or for acute use (which we also observed in the current study),33 but our findings of
increased risks of neurodevelopmental disorders at high doses or longer duration of cumulative
exposure have important clinical implications in women with chronic pain conditions or at risk of opioid
abuse.
The exact mechanism linking prenatal opioid exposure to neurodevelopmental disorders is not fully
delineated. However, opioids are known to readily cross the placenta, are present in breast milk of
opioid exposed mothers, and have been reported to be capable of altering fetal brain development,
particularly in women with a history of substance abuse.16,34 Volumetric measurements of the cerebral
characteristics of children exposed to opiates during pregnancy indicated smaller intracranial and brain
volumes including the cerebral cortex, amygdala, brainstem, cerebellar cortex and thinner cortex of the
right lateral orbitofrontal cortex compared to unexposed infants.35,36 Alterations of the hippocampal
cholinergic system and opiate receptor system has also been hypothesized in literature.34,37–39 More so,
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morphine induces apoptosis of the human microglia and neurons.34 Since several regions of the brain
such as the limbic system, midbrain and thalamus contain the highest concentration of opioid receptors,
it has been postulated that inappropriate activation of these receptors can alter the normal fetal brain
development.40
So far, evidence on this potential safety issue in human clinical studies has largely accrued from studies
evaluating illicit heroin or methadone, mothers with diagnosis of substance misuse, drug dependence or
OUDs, and infants with neonatal abstinence syndrome (eTable 1). Therefore, the association between
maternal opioid exposure and the risk of neurodevelopmental disorders in the general population is
largely unknown. Since we excluded mothers with history of OUDs and less than 0.1% of the included
mothers in our study cohort had a history of substance misuse, it is difficult to index our findings to the
studies previously reported in literature. To our knowledge, results at 3 and 5 years old from the
Norwegian Mother and Child Cohort (MoBa) study by Skovlund et al evaluating maternal opioid use and
language competencies and communications skills in children represent the only other large populationbased reports evaluating this safety concern.41,42 The authors reported no significant association
between prenatal opioid exposure and impairments in language competencies and communications
skills in children at 3 or 5 years of age, but noted that their study could not address opioid use with large
doses or long duration during pregnancy. While the results of our overall analysis are similar to the two
reports by Skovlund et al, the current study is different in a few ways. Unlike in Skovlund’s studies, we
did not rely on self-reports to assess exposure status or the incidence of neurodevelopmental outcomes
in children. While parental self-reporting is generally regarded as a valid tool for measuring
neurocognitive disorders in children,43,44 there is increased propensity for recall bias with self-reported
exposure. Moreover, differences between self-reported use of opioids during pregnancy compared to
dispensing information available in prescription records has been reported in the MoBa cohort.45
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Additionally, neurocognitive disorders in early childhood can occur as a constellation of overlapping
symptoms such that restricting to language disorders, while clinically relevant, may be too restrictive.
The current study has several strengths. First, our study provides updated information on the utilization
of opioids during pregnancy and extends the limited knowledge in literature on the risks associated with
in-utero opioid exposure in children. Second, we utilized a relatively large population size, utilized a
specific exposure definition and diagnoses for neurodevelopmental disorders as well as performed
several additional analyses to mitigate confounding and to assess the robustness of our findings. Most
importantly, our study provides much-needed data on relationship between cumulative dose, timing of
exposure, and duration of use of opioids during pregnancy and the risk of neurodevelopmental
disorders in children; information otherwise missing in the literature.
There are several limitations in the current study. Considering that administrative claims are not always
reported with fidelity, measurement errors including outcome and exposure misclassification may have
occurred, although more likely to be nondifferential. For example, exposure misclassification arising
from the use of unprescribed or illicit opioids may have occurred. Nevertheless, the observed strength
of association between our primary outcome and overall conclusions did not appreciably change with
alternative exposure or more conservative outcome definitions. Second, presence of
neurodevelopmental disorders is a dichotomous measure. It may therefore miss cognitive declines that
do not rise to the level of a diagnosis and may have less power compared to objective continuous
measures of cognitive abilities such as intelligence quotient (IQ). For example, in the NEAD study that
demonstrated robust effects of valproate on IQ, an analysis for the dichotomous measure of mental
retardation (i.e., <70 IQ) was not significant.46 As such, studies involving objective measures of cognitive
performance are needed to further evaluate this potential safety concern.
Despite our best efforts to address confounding by known and suspected confounders, our study results
may still be impacted by residual or unmeasured confounding arising from inadequate adjustments or
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incomplete information on important confounders such as maternal use of folic acid, breastfeeding
patterns after delivery, lifestyle factors such as alcohol drinking during pregnancy, severity of pain, and
heritability. Fourth, a variable that specifically captures the actual date of birth is absent from our data
set. While we relied on validated algorithms to estimate the pregnancy period,47,48 and results from the
replication of these methods in a database with clinically-documented date of birth (Supplementary
method/results) indicated the absence of substantial bias, our estimation of the pregnancy window may
still be prone to measurement error, albeit minimal. Fifth, although we included a relatively large
number of mother-infant pairs, we observed low rates of neurodevelopmental disorders in children;
thus, there is the concern of limited statistical power. Additionally, our findings may have been impacted
by the relatively short duration of follow-up (about 2 years) as some relevant neurodevelopmental
outcomes may go undetected in early infancy until later in childhood. Conversely, we may have
inaccurately included false positives; that is, individuals who experienced improvements in intellectual
and cognitive function later in childhood.
Finally, our study population comprises predominantly of mothers and children potentially of higher
socioeconomic status or those eligible for enrollment in private health plans. Therefore, our findings
may not be generalizable to uninsured or Medicaid enrolled mothers who are typically of lower
socioeconomic status and thus may have a higher prevalence of risk factors predisposing children to
higher risks of neurodevelopmental disorders. This specific limitation is however unrelated to the
internal validity of our study.
Conclusions
Although our overall results indicate the absence of a significant association, offspring of exposed
mothers prescribed opioids for a longer period or at higher cumulative dose during pregnancy had
significantly increased risk of neurodevelopmental disorders. These findings emphasize the need for
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careful evaluation of risks versus potential benefits in pregnant women requiring long-term opioid
therapy. Further research is needed to confirm and extend the findings of our study.
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Table 1: Selected baseline characteristics of women by maternal prescription opioid use
Characteristics
Unmatched cohort

Maternal age at delivery
Mean age, SD
< 18
18 - 24
25 - 34
≥ 35
Year of birth
2010
2011
2012
Geographic region
Northeast
Midwest
South
West
Unknown
Obstetric characteristics
Tobacco use
Obesity
Multiple gestation
Substance use and abuse
Obesity
Comorbid conditions
Psychiatric conditions
Depression
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Propensity score adjusted cohort

Exposed
(n=1899; 7.6%)

Unexposed
(n=23,013; 92.4%)

Standardized
difference

Exposed
(n=1899; 7.6%)

Unexposed
(n=22,958; 92.4%)

Standardized
difference

30.7 (4.3)
3 (0.2)
124 (6.5)
1464 (77.1)
308 (16.2)

30.5 (4.1)
51 (0.2)
1421 (6.2)
18292 (79.5)
3249 (14.1)

0.040
-0.015
0.015
-0.058
0.059

30.7 (4.3)
3 (0.2)
124 (6.5)
1462 (77.1)
308 (16.2)

30.7 (4.2)
36 (0.2)
1517 (6.6)
17664 (76.9)
3742 (16.3)

-0.040
0.000
-0.003
0.003
-0.002

3 (0.2)
1057 (55.7)
839 (44.2)

49 (0.2)
12171 (52.9)
10793 (46.9)

-0.013
0.056
-0.055

3 (0.2)
1056 (55.7)
838 (44.2)

35 (0.2)
12909 (56.2)
10015 (43.6)

0.001
-0.011
0.011

71 (3.7)
483 (25.4)
782 (41.2)
553 (29.1)
10 (0.5)

1495 (6.5)
6587 (28.6)
8676 (37.7)
6157 (26.8)
98 (0.4)

-0.125
-0.072
0.071
0.053
0.015

70 (3.7)
482 (25.4)
782 (41.2)
553 (29.2)
10 (0.5)

892 (3.9)
5751 (25)
9387 (40.9)
6813 (29.7)
117 (0.5)

-0.010
0.008
0.007
-0.011
0.002

50 (2.6)
66 (3.5)
9 (0.5)
2 (0.1)
66 (3.5)

319 (1.4)
615 (2.7)
58 (0.3)
10 (0)
615 (2.7)

0.089
0.047
0.037
0.023
0.047

50 (2.6)
66 (3.5)
9 (0.5)
2 (0.1)
66 (3.5)

601 (2.6)
820 (3.6)
108 (0.5)
22 (0.1)
820 (3.6)

0.002
0.014
0.000
-0.010
0.014

123 (6.5)

797 (3.5)

0.139

122 (6.4)

1459 (6.4)

0.028
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Anxiety
108 (5.7)
856 (3.7)
0.093
107 (5.6)
1263 (5.5)
ADHD
26 (1.4)
164 (0.7)
0.065
26 (1.4)
315 (1.4)
Bipolar disorder
10 (0.5)
39 (0.2)
0.061
9 (0.5)
112 (0.5)
Epilepsy
4 (0.2)
33 (0.1)
0.016
4 (0.2)
46 (0.2)
ADHD
26 (1.4)
164 (0.7)
0.065
26 (1.4)
315 (1.4)
Pain conditions
Fibromyalgia
52 (2.7)
417 (1.8)
0.062
52 (2.7)
628 (2.7)
Migraine
196 (10.3)
934 (4.1)
0.244
195 (10.3)
2330 (10.2)
Back pain
510 (26.9)
3707 (16.1)
0.264
510 (26.9)
6407 (27.9)
Other maternal illnesses
Diabetics
29 (1.5)
302 (1.3)
0.018
29 (1.5)
344 (1.5)
Hypertension
44 (2.3)
321 (1.4)
0.068
44 (2.3)
522 (2.3)
Renal disease
12 (0.6)
57 (0.2)
0.058
12 (0.6)
144 (0.6)
Concomitant medication use
Psychotropic medications
Benzodiazepines
121 (6.4)
504 (2.2)
0.208
120 (6.3)
1392 (6.1)
Antidepressants
240 (12.6)
1323 (5.7)
0.240
239 (12.6)
2870 (12.5)
Psychostimulants
44 (2.3)
248 (1.1)
0.096
44 (2.3)
522 (2.3)
Antipsychotics
5 (0.3)
36 (0.2)
0.023
4 (0.2)
57 (0.2)
Other medications
Antidiabetics
57 (3)
430 (1.9)
0.074
57 (3)
693 (3)
Antihypertensives
79 (4.2)
467 (2)
0.123
79 (4.2)
898 (3.9)
Antiepileptics
38 (2)
141 (0.6)
0.122
37 (2)
393 (1.7)
Maternal comorbidity makers
Maternal comorbidity index, mean (SD)
0.4 (0.8)
0.3 (0.7)
0.068
0.4 (0.8)
0.4 (0.8)
Number of hospitalizations
1.2 (2.7)
1.1 (1.9)
0.039
1.2 (2.7)
1.2 (2.7)
Length of hospitalization, mean (SD)
0.4 (0.5)
0.5 (0.5)
-0.043
0.4 (0.5)
0.4 (0.5)
Number of outpatient visits, mean (SD)
33.4 (25)
30.9 (24.2)
0.100
33.4 (25.0)
32.7 (26.8)
Abbreviations. ADHD, attention-deficit hyperactivity disorder; PS, propensity scores. Unless otherwise stated, number (%) are presented.
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0.024
-0.002
0.018
0.017
-0.002
0.004
0.005
-0.019
-0.011
0.010
0.001

0.018
0.030
0.005
-0.003
-0.005
0.022
0.028
0.015
0.023
0.031
0.027

Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Children
Table 2: Hazards ratio of the risk of neurodevelopmental disorders in children by maternal exposure to opioids
Outcome
Total number
Cases, n (%) Incidence rate per 1000 PY Crude HR (95% CI)
Adjusted HR (95% CI) a
Neurodevelopmental disorders
Unexposed
23013
1951 (8.5)
34.7
1
1
Exposed
1899
187 (9.9)
42.0
1.22 (1.05, 1.41)
1.16 (0.99, 1.34)
Developmental disorders
Unexposed
23013
1292
22.9
1
1
Exposed
1899
120
26.9
1.17 (0.97, 1.42)
1.10 (0.89, 1.36)
Abbreviations. HR, Hazards ratio; PY, person-years; n, number. a Adjusted HRs and 95% CI were obtained using propensity score by fine
stratification
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Table 3: Sensitivity analyses of the risk of neurodevelopmental disorders in children by maternal opioid use
Additional analyses
Total number
Case
IR per 1000
Unadjusted HR
Adjusted HR a
PY
Timing of exposure during pregnancy
23013
1951
Unexposed
34.7
1
1
First trimester alone
653
66
42.7
1.23 (0.98, 1.58)
1.10 (0.86, 1.41)
Second trimester alone
395
36
39.8
1.15 (0.83, 1.62)
1.11 (0.80, 1,54)
Third trimester alone
672
66
41.3
1.19 (0.94, 1.54)
1.20 (0.94, 1.54)
Cumulative duration of use during pregnancy
23013
1951
Unexposed
34.7
1
1
Less than 14 days
1717
163
40.2
1.20 (1.03, 1.40)
1.12 (0.95, 1.31)
At least 14 days
182
24
59.0
1.72 (1.16, 2.53)
1.66 (1.10, 2.48)
b
Cumulative dose
23013
1951
Unexposed
34.7
1
1
Low dose (<37.5 MME)
986
88
38.8
1.14 (0.92, 1.40)
1.10 (0.87, 1.36)
High dose (≥37.5 MME)
913
99
45.3
1.36 (1.12, 1.65)
1.21 (1.01, 1.49)
Alternative outcome definitions
>= 2 mental disorder claims
23013
1462
Unexposed
26.0
1
1
Exposed
1899
133
29.8
1.15 (0.97, 1.38)
1.10 (0.91, 1.35)
>=2 mental disorders claims filled on >=2 separate days
23013
1023
Unexposed
18.2
1
1
Exposed
1899
89
20.0
1.10 (0.89, 1.37)
1.06 (0.84, 1.34)
Analysis in restricted cohort with diagnosis of pain or
mental disorders, or receipt of psychostimulants
Unexposed
12337
823
27.8
1
1
Exposed
1246
95
32.9
1.20 (1.01, 1.44)
1.16 (0.94, 1.44)
Abbreviations. HR: hazards ratio; IR: incidence rate; PY: person-years; MME: morphine milligram equivalent. a Adjusted HRs and 95% CI were
obtained using propensity score by fine stratification. b Fetal cumulative opioid exposure was categorized by median split of the total opioid
doses during pregnancy. The low and high categories correspond to 2.25 – 37.4 MME and 37.5 – 2250 MME respectively.
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